Eli Lilly clears a trillion dollar milestone, shares extend record run on NYSE

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-28, 09:27.

Eli Lilly & Co. (US5324571083) has crossed a notable threshold on Wall Street. The New York-listed S&P 500 heavyweight now stands as the first pharmaceutical group to reach a market capitalization around the trillion dollar mark, with its shares at record highs according to recent analyst commentary. Zacks analysis on the valuation milestone

What recent reports highlight

Recent coverage from Zacks places Eli Lilly’s equity valuation above USD 1 trillion, noting that the stock has surged to levels above USD 1,000 per share amid strong demand for obesity medicines and a robust pipeline. Zacks report on Eli Lilly’s record highs A separate update from MarketBeat shows the shares closing at USD 1,206.51 on the NYSE on June 26, a gain of nearly 7 percent for that day. MarketBeat price and news overview

Simply Wall St points to two fresh regulatory drivers behind the latest move. The first is a positive opinion from the European Medicines Agency’s human medicines committee for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia across treatment lines, the second a U.S. Medicare GLP-1 Bridge program that improves access to Eli Lilly’s incretin-based weight management drugs Zepbound and Foundayo at a fixed monthly copay. Simply Wall St note on EMA and Medicare decisions

How analysts are positioned

Analyst sentiment on Eli Lilly remains constructive. Leerink, as cited by a recent Yahoo Finance article, lifted its price target on the stock to USD 1,232 from USD 1,119 on June 25 while reiterating an Outperform rating, reflecting continued confidence in earnings growth from obesity and diabetes franchises. Yahoo Finance summary of Leerink’s rating update Zacks, meanwhile, currently assigns Eli Lilly a Rank #3 (Hold) even after what it describes as a more than 15 percent surge over the month to new all-time highs, underlining that much of the near-term upside may already be reflected in the price. Zacks commentary on Eli Lilly’s momentum and rating

Beyond obesity, the company is expanding its reach in neurodegeneration. Yahoo Finance notes a June 22 research and collaboration agreement with Sweden’s BioArctic AB, combining BioArctic’s BrainTransporter technology with an undisclosed Eli Lilly drug candidate. BioArctic receives USD 30 million upfront, with potential milestone payments up to USD 770 million and tiered mid-single-digit royalties on future global sales if a product reaches the market. Yahoo Finance coverage of the BioArctic collaboration

The business behind the stock

Eli Lilly’s recent valuation is driven primarily by its portfolio of innovative medicines in obesity, diabetes and oncology. A central product line is its GLP-1-based obesity therapies, including Zepbound and Foundayo, which the Medicare GLP-1 Bridge program is set to support at a monthly copay, widening access for eligible U.S. patients. Simply Wall St description of Eli Lilly’s obesity portfolio and access program Alongside incretin therapies, oncology candidates such as Jaypirca add another pillar of growth as regulators broaden treatment windows.

Where the stock trades today

The Eli Lilly shares (US5324571083) most actively trade on the NYSE under the ticker LLY. As of 2026-06-26, 16:00 Eastern, the stock closed at USD 1,206.51, with an after-hours indication of USD 1,211.50 reported later that day, underscoring the current record territory. MarketBeat closing price and extended-hours data

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any securities. All data and assessments are based on sources cited and believed to be reliable at the time of publication.